GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Outset Medical Inc (NAS:OM) » Definitions » Beneish M-Score

Outset Medical (Outset Medical) Beneish M-Score : -3.26 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Outset Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.26 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Outset Medical's Beneish M-Score or its related term are showing as below:

OM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.54   Med: -3.26   Max: -3.15
Current: -3.26

During the past 6 years, the highest Beneish M-Score of Outset Medical was -3.15. The lowest was -3.54. And the median was -3.26.


Outset Medical Beneish M-Score Historical Data

The historical data trend for Outset Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outset Medical Beneish M-Score Chart

Outset Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -3.15 -3.54 -3.26

Outset Medical Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.54 -3.36 -3.27 -3.39 -3.26

Competitive Comparison of Outset Medical's Beneish M-Score

For the Medical Devices subindustry, Outset Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outset Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Outset Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Outset Medical's Beneish M-Score falls into.



Outset Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Outset Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0397+0.528 * 0.6949+0.404 * 1.1205+0.892 * 1.13+0.115 * 0.8011
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.963+4.679 * -0.132007-0.327 * 1.5739
=-3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $33.0 Mil.
Revenue was 30.507 + 30.362 + 36.04 + 33.467 = $130.4 Mil.
Gross Profit was 7.712 + 7.157 + 7.703 + 6.428 = $29.0 Mil.
Total Current Assets was $291.2 Mil.
Total Assets was $313.8 Mil.
Property, Plant and Equipment(Net PPE) was $18.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.8 Mil.
Selling, General, & Admin. Expense(SGA) was $141.5 Mil.
Total Current Liabilities was $55.3 Mil.
Long-Term Debt & Capital Lease Obligation was $134.6 Mil.
Net Income was -38.6 + -46.18 + -44.046 + -43.971 = $-172.8 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was -24.442 + -33.999 + -28.176 + -44.756 = $-131.4 Mil.
Total Receivables was $28.1 Mil.
Revenue was 32.007 + 27.761 + 25.057 + 30.55 = $115.4 Mil.
Gross Profit was 5.273 + 4.336 + 3.782 + 4.442 = $17.8 Mil.
Total Current Assets was $373.6 Mil.
Total Assets was $400.1 Mil.
Property, Plant and Equipment(Net PPE) was $22.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.2 Mil.
Selling, General, & Admin. Expense(SGA) was $130.0 Mil.
Total Current Liabilities was $51.9 Mil.
Long-Term Debt & Capital Lease Obligation was $101.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(32.98 / 130.376) / (28.07 / 115.375)
=0.252961 / 0.243294
=1.0397

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(17.833 / 115.375) / (29 / 130.376)
=0.154566 / 0.222434
=0.6949

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (291.219 + 18.648) / 313.801) / (1 - (373.645 + 21.993) / 400.115)
=0.012537 / 0.011189
=1.1205

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=130.376 / 115.375
=1.13

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.169 / (5.169 + 21.993)) / (5.81 / (5.81 + 18.648))
=0.190303 / 0.23755
=0.8011

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(141.463 / 130.376) / (129.997 / 115.375)
=1.085039 / 1.126735
=0.963

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((134.595 + 55.323) / 313.801) / ((101.912 + 51.949) / 400.115)
=0.605218 / 0.384542
=1.5739

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-172.797 - 0 - -131.373) / 313.801
=-0.132007

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Outset Medical has a M-score of -3.26 suggests that the company is unlikely to be a manipulator.


Outset Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Outset Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Outset Medical (Outset Medical) Business Description

Traded in Other Exchanges
N/A
Address
3052 Orchard Drive, San Jose, CA, USA, 95134
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
Executives
Leslie Trigg director, officer: President & CEO C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Marc Nash officer: SVP, Operations and R&D 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Jean-olivier Racine officer: Chief Technology Officer 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Nabeel Ahmed officer: Interim CFO 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Stacey L. Porter officer: Chief People Officer 3052 ORCHARD DRIVE, SAN JOSE CA 95134
John L. Brottem officer: General Counsel 3052 ORCHARD DR., SAN JOSE CA 95134
Steven S. Williamson officer: Chief Commercial Officer C/O HOLOGIC, INC., BEDFORD MA 01730
Martin Vazquez officer: Chief Operating Officer 3052 ORCHARD DR., SAN JOSE CA 95134
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Dale E Jones director C/O HUGHES SUPPLY INC, 20 N ORANGE AVE, ORLANDO FL 32801
D Keith Grossman director
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Warburg Pincus Llc director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017

Outset Medical (Outset Medical) Headlines

From GuruFocus